Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,219
datasets available to search
ShareScore release 0.9.0
Dataset results
1,219 results for “randomisation”
Data from: Economic evaluation of a general hospital unit for older people with delirium and dementia (TEAM randomised controlled trial)
Background: One in three hospital acute medical admissions is of an older person with cognitive impairment. Their outcomes are poor and the quality of their care in hospital has been criticised. A specialist unit to care for older people with delirium and dementia (the Medical and Mental Health Unit, MMHU) was developed and then tested in a randomised controlled trial where it delivered significantly higher quality of, and satisfaction with, care, but no significant benefits in terms of health status outcomes at three months. Objective: To examine the cost-effectiveness of the MMHU for older people with delirium and dementia in general hospitals, compared with standard care. Methods: Six hundred participants aged over 65 admitted for acute medical care, identified on admission as cognitively impaired, were randomised to the MMHU or to standard care on acute geriatric or general medical wards. Cost per quality adjusted life year (QALY) gained, at 3-month follow-up, was assessed in trial-based economic evaluation (599/600 participants, intervention: 309). Multiple imputation and complete-case sample analyses were employed to deal with missing QALY data (55%). Results: The total adjusted health and social care costs, including direct costs of the intervention, at 3 months was £7714 and £7862 for MMHU and standard care groups, respectively (difference -£149 (95% confidence interval [CI]: -298, 4)). The difference in QALYs gained was 0.001 (95% CI: -0.006, 0.008). The probability that the intervention was dominant was 58%, and the probability that it was cost-saving with QALY loss was 39%. At £20,000/QALY threshold, the probability of cost-effectiveness was 94%, falling to 59% when cost-saving QALY loss cases were excluded. Conclusions: The MMHU was strongly cost-effective using usual criteria, although considerably less so when the less acceptable situation with QALY loss and cost savings were excluded. Nevertheless, this model of care is worthy of further evaluation.
Study design factors influencing patients' willingness to participate in clinical research: a randomised vignette-based study
<p><b>Background:</b> High patient participation in clinical research reduces selection bias, and ensures the generalisability of study findings. We explored study-related factors that may influence patients' willingness to participate in research.</p> <p><b>Methods:</b> We submitted by mail two vignettes that described clinical research studies – a drug trial, and a diagnostic study – to patients recently discharged from hospital, and assessed</p> <p><b>Background:</b> High patient participation in clinical research reduces selection bias, and ensures the generalisability of study findings. We explored study-related factors that may influence patients' willingness to participate in research.</p> <p><b>Methods:</b> We submitted by mail two vignettes that described clinical research studies – a drug trial, and a diagnostic study – to patients recently discharged from hospital, and assessed their willingness to participate. We used a factorial design to randomly allocate three study attributes per vignette: in the drug trial, presumed superiority of new drug versus equipoise, public versus industry funding, and random versus non-random treatment allocation; in the diagnostic study, common versus rare disease, genetic versus protein analysis, and automatic reporting of results versus reporting on demand.</p> <p><b>Results:</b> Of 2600 patients contacted, 1140 (44%) participated. Globally, willingness to participate in a drug trial was lower than in a diagnostic study (44.8% <i>vs</i>. 76.2%; <i>P</i> <0.001). In the drug trial, participation was significantly higher when the new drug was presented as presumably better than the old (<i>vs</i>. equipoise) and when the study was funded by public sources (<i>vs</i>. industry), but was not affected by the allocation method. None of the factors tested in the diagnostic study was associated with participation.</p> <p><b>Conclusions:</b> Patients were more likely to participate in a hypothetical observational diagnostic study than in a hypothetical drug trial. Participation in the trial was lower when clinical equipoise was expressed, and when the trial was funded by industry. These results suggest that some features of study design can influence participation.their willingness to participate. We used a factorial design to randomly allocate three study attributes per vignette: in the drug trial, presumed superiority of new drug versus equipoise, public versus industry funding, and random versus non-random treatment allocation; in the diagnostic study, common versus rare disease, genetic versus protein analysis, and automatic reporting of results versus reporting on demand.</p>
Data from: The effect of meal frequency in a reduced-energy regimen on the gastrointestinal and appetite hormones in patients with type 2 diabetes: a randomised crossover study
Background: Appetite and gastrointestinal hormones (GIHs) participate in energy homeostasis, feeding behavior and regulation of body weight. We demonstrated previously the superior effect of a hypocaloric diet regimen with lower meal frequency (B2) on body weight, hepatic fat content, insulin sensitivity and feelings of hunger compared to the same diet divided into six smaller meals a day (A6).Studies with isoenergetic diet regimens indicate that lower meal frequency should also have an effect on fasting and postprandial responses of GIHs.The aim of this secondary analysis was to explore the effect of two hypocaloric diet regimens on fasting levels of appetite and GIHs and on their postprandial responses after a standard meal. It was hypothesized that lower meal frequency in a reduced-energy regimen leading to greater body weight reduction and reduced hunger would be associated with decreased plasma concentrations of GIHs: gastric inhibitory peptide (GIP), glucagon-like peptide-1(GLP-1), peptide YY(PYY), pancreatic polypeptide (PP) and leptin and increased plasma concentration of ghrelin. The postprandial response of satiety hormones (GLP-1, PYY and PP) and postprandial suppression of ghrelin will be improved. Methods: In a randomized crossover study, 54 patients suffering from type 2 diabetes (T2D) underwent both regimens.The concentrations of GLP-1, GIP, PP, PYY, amylin, leptin and ghrelin were determined using multiplex immunoanalyses. Results: Fasting leptin and GIP decreased in response to both regimens with no difference between the treatments (p=0.37 and p=0.83, respectively). Fasting ghrelin decreased in A6 and increased in B2 (with difference between regimens p=0.023). Fasting PP increased in B2with no significant difference between regimens (p=0.17). Neither GLP-1 nor PYY did change in either regimen. The decrease in body weight correlated negatively with changes in fasting ghrelin (r=-0.4, p<0.043) and the postprandial reduction of ghrelin correlated positively with its fasting level (r=0.9, p<0.001). The postprandial responses of GIHs and appetite hormones were similar after both diet regimens. Conclusions: Both hypocaloric diet regimens reduced fasting leptin and GIP and postprandial response of GIP comparably. The postprandial responses of GIHs and appetite hormones were similar after both diet regimens. Eating only breakfast and lunch increased fasting plasma ghrelin more than the same caloric restriction split into six meals. The changes in fasting ghrelin correlated negatively with the decrease in body weight. These results suggest that for type 2 diabetic patients on a hypocaloric diet, eating larger breakfast and lunch may be more efficient than six smaller meals during the day.
Data from: The Fear Reduction Exercised Early (FREE) approach to management of low back pain in general practice: a pragmatic cluster-randomised controlled trial
Background: Effective and cost-effective primary care treatments for low back pain (LBP) are required to reduce the burden of the world's most disabling condition. This study aimed to compare the clinical effectiveness and cost-effectiveness of the Fear Reduction Exercised Early (FREE) approach to LBP (intervention) with usual general practitioner (GP) care (control). Methods and findings: This pragmatic, cluster-randomised controlled trial with process evaluation and parallel economic evaluation was conducted in the Hutt Valley, New Zealand. Eight general practices were randomly assigned (stratified by practice size) with a 1:1 ratio to intervention (4 practices; 34 GPs) or control group (4 practices; 29 GPs). Adults presenting to these GPs with LBP as their primary complaint were recruited. GPs in the intervention practices were trained in the FREE approach, and patients presenting to these practices received care based on the FREE approach. The FREE approach restructures LBP consultations to prioritise early identification and management of barriers to recovery. GPs in control practices did not receive specific training for this study, and patients presenting to these practices received usual care. Between 23 September 2016 and 31 July 2017, 140 eligible patients presented to intervention practices (126 enrolled) and 110 eligible patients presented to control practices (100 enrolled). Patient mean age was 46.1 years (SD 14.4), and 46% were female. The duration of LBP was less than 6 weeks in 88% of patients. Primary outcome was change from baseline in patient participant Roland Morris Disability Questionnaire (RMDQ) score at 6 months. Secondary patient outcomes included pain, satisfaction, and psychosocial indices. GP outcomes included attitudes, knowledge, confidence, and GP LBP management behaviour. There was active and passive surveillance of potential harms. Patients and outcome assessors were blind to group assignment. Analysis followed intention-to-treat principles. A total of 122 (97%) patients from 32 GPs in the intervention group and 99 (99%) patients from 25 GPs in the control group were included in the primary outcome analysis. At 6 months, the groups did not significantly differ on the primary outcome (adjusted mean RMDQ score difference 0.57, 95% CI −0.64 to 1.78; p = 0.354) or secondary patient outcomes. The RMDQ difference met the predefined criterion to indicate noninferiority. One control group participant experienced an activity-related gluteal tear, with no other adverse events recorded. Intervention group GPs had improvements in attitudes, knowledge, and confidence compared with control group GPs. Intervention group GP LBP management behaviour became more guideline concordant than the control group. In cost-effectiveness, the intervention dominated control with lower costs and higher Quality-Adjusted Life Year (QALY) gains. Limitations of this study were that although adequately powered for primary outcome assessment, the study was not powered for evaluating some employment, healthcare use, and economic outcomes. It was also not possible for research nurses (responsible for patient recruitment) to be masked on group allocation for practices. Conclusions: Findings from this study suggest that the FREE approach improves GP concordance with LBP guideline recommendations but does not improve patient recovery outcomes compared with usual care. The FREE approach may reduce unnecessary healthcare use and produce economic benefits. Work participation or health resource use should be considered for primary outcome assessment in future trials of undifferentiated LBP.
Data from: Ibobbly mobile health intervention for suicide prevention in Australian Indigenous youth: a pilot randomised controlled trial
Objectives: Rates of youth suicide in Australian Indigenous communities are four times the national youth average and demand innovative interventions. Historical and persistent disadvantage is coupled with multiple barriers to help-seeking. Mobile phone applications offer the opportunity to deliver therapeutic interventions directly to individuals in remote communities.The pilot study aimed to evaluate the effectiveness of a self-help mobile app (ibobbly) targeting suicidal ideation, depression, psychological distress, and impulsivity among Indigenous youth in remote Australia. Setting: Remote and very remote communities in the Kimberley region of north Western Australia Participants: Indigenous Australians aged 18-35 years. Interventions: 61 participants were recruited and randomised to receive either an app (ibobbly) which delivered acceptance-based therapy over 6 weeks or were waitlisted for 6 weeks and then received the app for the following 6 weeks. Primary and secondary outcome measures: The primary outcome was the Depressive Symptom Inventory – Suicidality Subscale (DSI-SS) to identify the frequency and intensity of suicidal ideation in the previous weeks. Secondary outcomes were the Patient Health Questionnaire 9 (PHQ-9), the Kessler Psychological Distress Scale (K10), and the Barratt Impulsivity Scale (BIS-11). Results: Although pre- post-intervention change on the (DSI-SS) was significant in the ibobbly arm (t=2•40; df=58•1; p=0•0195), this difference was not significant compared to the waitlist arm (t=1•05; df=57•8; p=0•2962). However, participants in the ibobbly group showed substantial and statistically significant reductions in PHQ-9 and K10 scores compared to waitlist. No differences were observed in impulsivity. Waitlist participants improved after 6 weeks of app use. Conclusions: Apps for suicide prevention reduce distress and depression but do not show significant reductions on suicide ideation or impulsivity. A feasible and acceptable means of lowering symptoms for mental health disorders in remote communities is via appropriately designed self-help apps. Trial Registration: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12613000104752.
Data from: Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial.
BACKGROUND: Retained placenta is associated with post-partum haemorrhage. Meta-analysis has suggested that umbilical injection of oxytocin could increase placental expulsion without the need for a surgeon or anaesthetic. We assessed the effect of high-dose umbilical vein oxytocin as a treatment for retained placenta. METHODS: In this double-blind, placebo-controlled trial, haemodynamically stable women with a retained placenta for more than 30 min were recruited from 13 sites in the UK, Uganda, and Pakistan. 577 women were randomly assigned by a computer-generated randomisation list stratified by centre to 30 mL saline containing either 50 IU oxytocin (n=292) or 5 mL water (n=285), which was injected into the placenta through an umbilical vein catheter. All trial participants, study workers, and data handlers were masked to individual allocations. The primary outcome was the need for manual removal of the placenta. Analysis was by intention to treat. This study is registered, number ISRCTN 13204258. FINDINGS: The primary outcome was recorded for all participants. We detected no difference between the groups in the need for manual removal of placenta (oxytocin 179/292 [61.3%] vs placebo 177/285 [62.1%]; relative risk 0.98, 95% CI 0.87-1.12; p=0.84). The need for manual removal was higher in the UK (overall 250/361 [69%]) than in Uganda (90/190 [47%]) or Pakistan (16/26 [62%]). Adverse events did not differ between the two groups. INTERPRETATION: Umbilical oxytocin has no clinically significant effect on the need for manual removal for women with retained placenta. FUNDING: WHO, WellBeing of Women, Pakistan Higher Education Commission.
Summary statistics of eQTLs obtained from single-nuclei RNA-seq in 8 major brain cell-types for mendelian randomisation
<p>This dataset contains <em>cis</em>-eQTL summary statistics for 8 brain cell-types, generated on a snRNA-seq dataset on post-mortem brains from 391 individuals (full), as well as a controls-only (subset of full, 183 individuals).</p> <p>Genotype dosage matrices were obtained with <code>SeqArray</code>, where 0 = homozygous alt, 1 = heterozygous, 2 = homozygous ref https://bioconductor.org/packages/release/bioc/manuals/SeqArray/man/SeqArray.pdf . The eQTL models as applied by <code>MatrixEQTL</code> therefore use "ref" as the effect allele (as implemented in their additive model).</p> <p>The eQTL summary statistics for within the "full" and "controls-only" dataset have been packed into <code>.tar.gz</code> files for each cell-type, where unpacking will yield summary statistics by chromosome. Each file contains the following columns;</p> <p>1. <code>SNP</code> (in rsid format)</p> <p>2. <code>gene</code> (in symbol format)</p> <p>3. <code>t.stat</code> (t-statistic as determined by MatrixEQTL)</p> <p>4. <code>p.value</code> (linear model association p-value)</p> <p>5. <code>FDR</code> (false discovery rate as determined by MatrixEQTL)</p> <p>6. <code>beta</code> (effect size / slope of the linear model)</p> <p>7. <code>chrom</code> (chromosome in "chrN" format)</p> <p>8. <code>position</code> (SNP position, hg38 build)</p> <p>9. <code>effect_allele</code> (this is the "ref" allele as described above)</p> <p>10. <code>other_allele</code> (alternate allele)</p> <p>11. <code>maf</code> (minor allele frequency, as determined by SeqArray on this dataset)</p> <p> </p> <p>In addition, single-cell expression matrices in count format are available in the <code>single-cell_data.tar</code> archive for the full 391 individuals (2,348,438 cells). This archive contains processed single-cell counts as described in our manuscript for the 4 datasets included; "BRYOIS_192" (separated into "MS" and "AD" as per their publication), "MATTHEWS", "ROCHE_MPD92" and "MRC_60". In addition, a cell-level metadata file containing covariates and cell-type labels across all datasets is included (<code>cell_level_metadata.rds</code>). Cell barcodes and individual IDs have been renamed to preserve anonymity.</p> <p> </p> <p><strong>January 2025 update: </strong>Now published at <strong><em>Nature Genetics</em></strong>. <strong>https://www.nature.com/articles/s41588-024-02050-9</strong></p> <p><strong>May 2025 update: </strong>Added the aggregated pseudo "Bulk" eQTLs as seen in Fig 1. d. </p>
Blueprint for modelling time effects in a stepped-wedge, cluster-randomised trial
<div><strong># Project title</strong></div> <div>Blueprint for modelling time effects in a stepped-wedge, cluster-randomised trial</div> <div> </div> <div><strong># Brief project overview</strong></div> <div>This is Data coming out of the IPOS-Dem project, a Stepped-wedge Cluster Randomised Trial (SW-CRT). Please make shure to check out the SW-CRT protocol for more details at <a href="https://www.doi.org/10.1111/jan.14953">https://www.doi.org/10.1111/jan.14953</a>. </div> <div> </div> <div>We are currently working on our main study (SW-CRT) analysis. While we remain dedicated to open science, our priority is to ensure the utmost integrity of our ongoing research.</div> <div> </div> <div><strong># Contributors</strong></div> <div>Frank Spichiger, Andrea Koppitz, André Meichtry</div> <div> </div> <div><strong>## Repository overview</strong></div> <div> </div> <div>|-- readme.md</div> <div>|-- documentation</div> <div> |--readme.md</div> <div> |--Datadictionary.html</div> <div>|-- data</div> <div> |--readme.md</div> <div> |--IPOS-Dem_CH-SW-CRT_PLD_Qualidem.feather</div> <div> |--IPOS-Dem_CH-SW-CRT_PLD_locf_Qualidem.feather</div> <div> |--csv</div> <div> |--IPOS-Dem_CH-SW-CRT_PLD_Qualidem.csv</div> <div> |--IPOS-Dem_CH-SW-CRT_PLD_locf_Qualidem.csv</div> <div>|-- analysis</div> <div> |--readme.md</div> <div> |--240229_Analysis_Main.html</div> <div> |--240229_Analysis_Main.qmd</div> <div> |--grateful-refs.bib</div> <div> |--output</div> <div> |--models-REML.csv</div> <div> |--models.csv</div> <div> |--figures</div> <div> |--Conversions for plotting - 1.png</div> <div> |--Define Model 5-1.png</div> <div> |--Defining Model 4-1.png</div> <div> |--m1predictions.eps</div> <div> |--m1predictions.png</div> <div> |--m2predictions.eps</div> <div> |--m2predictions.png</div> <div> |--m3predictions.eps</div> <div> |--m3predictions.png</div> <div> |--m4predictions.eps</div> <div> |--m4predictions.png</div> <div> |--m5predictions.eps</div> <div> |--m5predictions.png</div> <div> |--Model 1 plot-1.png</div> <div> |--Model 1 plot-2.png</div> <div> |--Model 2 plot-1.png</div> <div> |--Model 2 plot-2.png</div> <div> |--Model 3 plot-1.png</div> <div> |--More plots for Model 1-1.png</div> <div> |--More plots for Model 1-2.png</div> <div> |--More plots for Model 4-1.png</div> <div> |--More plots for Model 5-1.png</div> <div> |--Plots for Model 4-1.png</div> <div> |--Plots for Model 5-1.png</div> <div> |--Plots for the other two models-1.png</div> <div> |--Plots for the other two models-2.png</div> <div> </div> <div> </div> <div># Applicable instructions</div> <div>The R markdown files were generated using R 4.2.2 in RStudio 2023.12.1 for MacOS X you can run them using free software but will need to install R, Rstudio and the packages cited at the end of the quarto or the rendered html we used.</div> <div> </div> <div># Additional resources</div> <div>- Main study protocol: <a href="https://www.doi.org/10.1111/jan.14953">https://www.doi.org/10.1111/jan.14953</a></div> <div>- QUALIDEM measure used: <a href="https://doi.org/10.1186/1477-7525-11-91">https://doi.org/10.1186/1477-7525-11-91</a> </div> <div>- Pos-Pal consortium with more information on the measure: <a href="https://www.pos-pal.org">https://www.pos-pal.org</a></div> <div>- IPOS-Dem translation and adaption: <a href="https://www.doi.org/10.1186/s41687-022-00420-7">https://www.doi.org/10.1186/s41687-022-00420-7</a></div> <div>- IPOS-Dem inter-rating reliability: <a href="https://doi.org/10.1371/journal.pone.0286557">https://doi.org/10.1371/journal.pone.0286557 </a></div>
Dataset underpinning "A pilot randomised trial of a brief virtual reality scenario in smokers unmotivated to quit: Assessing the feasibility of recruitment"
<p>This is the dataset underpinning the manuscript titled "A pilot randomised trial of a brief virtual reality scenario in smokers unmotivated to quit: Assessing the feasibility of recruitment".</p>
Feasibility and acceptability of a tailored health coaching intervention to improve type 2 diabetes self-management in Saudi Arabia: A mixed-methods randomised feasibility trial
<p><em>Background:</em> Around a third of the population of Saudi Arabia have been diagnosed with Type 2 diabetes, a condition often requiring lifestyle changes. Personalised health coaching, a strategy developed to assist individuals in overcoming challenges to adopt healthy behaviours, has not yet been widely applied in the country.</p> <p><em>Aims: </em>We aim to explore the feasibility and acceptability of tailored health coaching in Saudi Arabia, in order to help those with Type 2 diabetes to more effectively manage their condition.</p> <p><em>Methods:</em> Using a mixed-methods approach, this research involved a randomised controlled trial with 30 Saudi adults who have Type 2 diabetes. They were randomly allocated into either the intervention or control arm for 12 weeks. The Capability, Opportunity, Motivation, and Behaviour framework was used to guide the intervention implementation along with the Behaviour Change Techniques Taxonomy version 1. The primary goal was to assess the suitability and duration of the intervention, recruitment, retention, and completion rates. The secondary outcome focused on the preliminary efficacy of the health coaching measured by the glycaemic index, blood pressure, body mass index, waist circumference, weight, patient self-efficacy, and diabetes self-management.</p> <p><em>Results:</em> The results showed high rates of eligibility, recruitment, and retention (a screening rate of 90%, a recruiting rate of 79%, and a retention rate of 97%). Notable improvements were observed in the health coaching group across five outcomes: HbA1c, BMI, waist circumference, patient self-efficacy, and diabetes self-care. Qualitative findings highlighted the participants' perceived benefits from the intervention, including enhanced motivation, better understanding of diabetes management, and a supportive coaching relationship. Participants expressed high satisfaction with the intervention and advocated for its expansion.</p> <p><em>Conclusion:</em> The findings demonstrated positive outcomes, supporting the need for a larger randomised controlled trial to evaluate the efficacy of health coaching in improving diabetes self-management among individuals with Type 2 diabetes.</p>
PRISMA Flowchart for the systematic review: Impact on postoperative complications of combined prehabilitation targeting co-exisiting smoking, malnutrition, obesity, alcohol drinking, and physical inactivity: a systematic review and meta-analysis of randomised trials
<p><strong><span>PRISMA 2020 Flow Chart.</span></strong><span> “No predefined risk factors” covers studies with relevant multimodal interventions that were excluded due to lack of predefined risky lifestyles in the population. “Only trial registration or conference abstract” covers reports of these but with no subsequent publication. SNAP: Smoking, Nutrition (overweight/obesity, malnutrition), Alcohol or Physical inactivity.</span></p>
Direct pulp capping versus pulpotomy with MTA for carious primary molars: a 3-year randomised clinical trial
<p>Dataset for the analyses of the trial.</p>
Radix Sophorae flavescentis for chronic hepatitis B - Characteristics of potential randomised clinical trials
<p>This table listed the references considered to be potential randomised clinical trials on Radix Sophorae flavescentis for chronic hepatitis B, as we could not attain any response from the authors about their randomisation method. We also listed the results of contacting authors. </p> <p> </p>
Effects of continuous management on anxiety and depression after pacemaker implantation in the COVID-19 era:a randomised trial
Open the record for dataset details and reuse information.
A Randomised Study Evaluating Diagnostics of Pleural Effusion Among Patients Suspect of Cancer.
ClinicalTrials.gov study NCT04233359. IPD Sharing: NO. Countries: 1. Publications: 30.
Laparoscopic vs Ultrasound Guided TAP Block in Colorectal Surgery. A Randomised Controlled Study.
ClinicalTrials.gov study NCT04907461. IPD Sharing: NO. Countries: 1. Publications: 14.
Effects of Local Anesthetic or Saline Solution on Peripheral Nerve Stimulation - a Randomised Study
ClinicalTrials.gov study NCT00176111. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS
ClinicalTrials.gov study NCT01617226. IPD Sharing: Not stated. Countries: 1. Publications: 11.
A Comparison of Kneipp Hydrotherapy With Conventional Physiotherapy in the Treatment of Osteoarthritis of the Hip or Knee: Protocol of a Prospective Randomised Controlled Clinical Trial
ClinicalTrials.gov study NCT00950326. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Randomised Controlled Trial on LESS Versus Conventional Laparoscopic Appendicectomy.
ClinicalTrials.gov study NCT01203566. IPD Sharing: Not stated. Countries: 1. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.